India's first public sector proton beam therapy unit to come up in Assam; state signs MoU with Belgian firm

Assam has signed an MoU with Belgium-based Ion Beam Applications (IBA) to set up India's first public-sector proton beam therapy centre in Guwahati at a cost of Rs 600 crore. The facility will offer advanced cancer treatment, particularly for children, and is expected to take at least three years to become operational.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8QGNRKm
via IFTTT

Read More

Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lV5JvIn
via IFTTT

Read More

Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More

NPPA list brings little relief: No price cut for 25% cancer drugs

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hqpvYDO
via IFTTT

Read More

India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1prYPNv
via IFTTT

Read More

Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT

Read More

SC pulls up Centre over soaring medicine costs

The Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sandeep Mehta questioned the justification for significant price discrepancies faced by patients. The court highlighted a lack of accountability regarding how drug manufacturers benefit from inflated prices. Government representatives stated that regulatory measures should not encompass the entire drug pricing ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKD2ST4
via IFTTT

Read More

Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q27gIB0
via IFTTT

Read More

Healthware partners Fujifilm to expand use of precision surgical imaging solutions

Healthware has entered a partnership with Fujifilm to expand the use of intra-operative ultrasound systems across India. This collaboration aims to meet the critical clinical needs in complex surgeries. Real-time surgical ultrasound will be made available in more operating rooms, enhancing the speed of surgical procedures. The partnership combines technological innovation with clinical expertise for better patient outcomes. Healthware's national service and support network will facilitate this advancement in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R63ECuB
via IFTTT

Read More

Cipla expects US business to draw support from upcoming product pipeline

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/cipla-expects-us-business-to-draw-support-from-upcoming-product-pipeline/articleshow/135229843.cms
via IFTTT

Read More

Sakar Healthcare posts Rs 11 cr profit in Q2

The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrA53o
via IFTTT

Read More

Mankind Pharma shares key business developments from Q2 & H1 of FY27

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8DIvUoX
via IFTTT

Read More

Lord’s Mark Industries Limited becomes Asia’s first company to secure multiple US FDA registrations for 200+ surgical and hygiene products; US exports to begin in December

Silvassa manufacturing expansion completed ahead of schedule as the company prepares to expand its international footprint across the United States and South America

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z25eqPc
via IFTTT

Read More

Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y6PozZ
via IFTTT

Read More

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RCM4mj0
via IFTTT

Read More

One Science Nutrition: Building a science-led approach to sports nutrition

One Science Nutrition was co-founded by Aman and Aniket Vachher to create credible sports nutrition products. The brand aims to cater to evolving consumer expectations around product quality and transparency. Their product range includes various supplements that support diverse fitness goals and health benefits. Future strategies involve leveraging artificial intelligence to enhance consumer experiences and product discovery. The founders emphasize maintaining core values while pursuing growth in the nutrition industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90xr2IG
via IFTTT

Read More

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GY9MseC
via IFTTT

Read More

States urged to enforce ban on reuse of single-use medical devices

The Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some private hospitals have raised concerns regarding patient safety and regulatory compliance. The directive specifically targets misuse in high-stakes medical fields such as cardiology and neurosurgery. Monitoring and enforcement of compliance by healthcare establishments have been mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dTYQWjS
via IFTTT

Read More

Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say

Jubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure and refinance project-related liabilities at overseas subsidiaries. The proposed issuance, rated AA+ by India Ratings, could take place before the end of next month, according to two merchant bankers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5Ax9oDs
via IFTTT

Read More